Poshuvet Duo Sustained Release Tablet 5/500 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
MFDS item code 202204071 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This drug is used to assist dietary and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes suitable for the combination therapy of dapagliflozin and metformin. In case of type 2 diabetes patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors, the impact of dapagliflozin on the occurrence of cardiovascular events should be managed carefully according to expert guidelines. This drug can help manage cardiovascular health along with effective blood sugar control.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacologic treatment for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may affect glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who do not have other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).
This drug is used to treat diabetes and helps to control blood sugar. However, it may very rarely cause a dangerous condition known as lactic acidosis, so caution is necessary. Additionally, when used in conjunction with insulin or other diabetes medications, hypoglycemia may occur. This drug should not be used in patients with severely impaired kidney function, or those with acute illnesses such as dehydration or serious infections. Pregnant or breastfeeding women should also avoid this medication. Before taking this drug, it is crucial to check fluid status and kidney function, and symptoms of hypotension or changes in kidney function should be monitored closely during treatment. In particular, dosage should be adjusted carefully for elderly patients or those with impaired kidney function. This drug may increase the risk of genital infections and urinary tract infections; hence, any signs of infection should prompt immediate consultation with a physician. Furthermore, this drug may lower vitamin B12 levels, so regular monitoring of vitamin B12 is advisable during prolonged use. Excessive alcohol consumption increases risks, so alcohol should be avoided during treatment. Before and after surgical or radiological contrast examinations, discontinuation of this drug for a period is needed, followed by checking kidney function before resuming it. While taking this drug, patients should monitor for symptoms of hypoglycemia and dehydration, and report any abnormal signs to healthcare providers immediately. Lastly, safety has not been established in children and pregnant women, and careful management is necessary for the elderly.
Not everyone experiences these, and they can vary from person to person.
This drug may be sensitive to air or moisture, so it should be stored in a sealed container. The recommended storage temperature is at room temperature between 1 degree and 30 degrees. Proper storage helps maintain the drug's effectiveness for a longer period.
Orange, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.